0001654954-24-001964.txt : 20240220
0001654954-24-001964.hdr.sgml : 20240220
20240220161037
ACCESSION NUMBER: 0001654954-24-001964
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240220
DATE AS OF CHANGE: 20240220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: tsai chun-hsien
CENTRAL INDEX KEY: 0001859363
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41461
FILM NUMBER: 24653359
MAIL ADDRESS:
STREET 1: 8880 RIO SAN DIEGO DRIVE
STREET 2: SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ainos, Inc.
CENTRAL INDEX KEY: 0001014763
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 751974352
STATE OF INCORPORATION: TX
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
BUSINESS PHONE: 858-869-2986
MAIL ADDRESS:
STREET 1: AINOS, INC.
STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
FORMER COMPANY:
FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC
DATE OF NAME CHANGE: 19960516
4
1
section16.xml
PRIMARY DOCUMENT
X0508
4
2024-02-16
0001014763
Ainos, Inc.
AIMD
0001859363
tsai chun-hsien
8880RIOSANDIEGODR.#800
SANDIEGO
CA
92108
true
true
CEO, PRESIDENT, CHAIRMAN
false
COMMONSTOCK
2024-02-16
4
A
false
26100
0.8693
A
276219
D
RSU
2024-02-16
4
C
false
26100
D
COMMON
26100
161900
D
Reference is made to(i) 870,000RSUsthatweregrantedonAugust15,2023, adjusted to 174,000 shares giving effect to the 1 for 5 reverse share split on December 14, 2023, pursuanttotheCompany's2023StockIncentivePlan, with vesting occurring inincrementsof15%on2/15/24,15%on8/15/24,30%on8/15/25,and 40% on 8/15/26 subject to normal and customary termination events; and (ii) 50,000RSUsthatweregrantedpursuanttoanemploymentMandateAgreementdatedMarch17,2022, adjusted to 10,000 shares giving effect to the 1 for 5 reverse share split on December 14, 2023, andundertheCompany's2021StockIncentivePlan,andasamendedbyits2023StockIncentivePlan, with vesting occurringinincrementsof15%on4/24/23and10/24/23,30%on10/24/24and40%on10/24/25,subjecttonormalandcustomaryterminationevents
/s/ Chun-Hsien Tsai
2024-02-20